Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a T-cell product candidate for patients with systemic lupus ...

The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without ...

Dec. 11, 2024 — Many vitamins are produced in chemical factories, often synthetically, but researchers have succeeded in developing a natural and simple method for producing vitamin B2: by ...

Satellite images reveal Russian military equipment being prepared for loading, a possible prelude to its withdrawal from Syria. Travis Timmerman, an American who was found earlier this week, was ...

Dec. 12, 2024 — Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular ...